Published in Cancer Weekly, July 31st, 2001
The experimental studies were presented on June 23-24, 2001, at the annual meeting of the European Hematology Association in Frankfurt, Germany. In the first presentation, investigators from the University of Texas-San Antonio showed that Bcl-2 (the target of Genasense) was a major factor in the resistance of myeloma to standard chemotherapy. Genasense treatment markedly reduced...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.